Clinigen Group plc Director/PDMR Shareholding (6436E)

TIDMCLIN

RNS Number : 6436E

Clinigen Group plc

09 May 2017

9 May 2017

Director's Share Dealing

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services group, announces that it was notified on 5 May 2017 that the following transactions took place on 4 May 2017.

Peter George, Non-Executive Director, transferred 43,000 ordinary shares of 0.1 pence each in the Company at nil pence per share.

Following this transaction, Mr George's total beneficial interest in the Company is 3,314,242 ordinary shares, representing approximately 2.88 per cent of the current issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1     Details of the person discharging 
        managerial responsibilities/person 
        closely associated 
----  ------------------------------------------------------- 
 a)    Name                    Peter George 
----  ----------------------  ------------------------------- 
 2     Reason for the notification 
----  ------------------------------------------------------- 
 a)    Position/status         Non-Executive Director 
----  ----------------------  ------------------------------- 
 b)    Initial                 Initial Notification 
        notification 
        /Amendment 
----  ----------------------  ------------------------------- 
 3     Details of the issuer, emission allowance 
        market participant, auction platform, 
        auctioneer or auction monitor 
----  ------------------------------------------------------- 
 a)    Name                    Clinigen Group plc 
----  ----------------------  ------------------------------- 
 b)    Legal Entity            N/A 
        Identifier 
----  ----------------------  ------------------------------- 
 4     Details of the transaction(s): section 
        to be repeated for (i) each type 
        of instrument; (ii) each type of 
        transaction; (iii) each date; and 
        (iv) each place where transactions 
        have been conducted 
----  ------------------------------------------------------- 
 a)    Description             Ordinary shares of 0.1 pence 
        of the financial        each 
        instrument,             GB00B89J2419 
        type of 
        instrument 
        Identification 
        code 
----  ----------------------  ------------------------------- 
 b)    Nature of               Transfer of shares 
        the transaction 
----  ----------------------  ------------------------------- 
 c)    Currency                GBP 
----  ----------------------  ------------------------------- 
 d)    Price(s)                  Price(s)        Volume(s) 
        and volume(s) 
----  ----------------------  --------------  --------------- 
                                    0p             43,000 
 ---------------------------  --------------  --------------- 
 
 e)    Aggregated               43,000 
        information 
   - Aggregated                  0p 
    volume 
   - Price                       Nil 
   - Aggregated 
    total 
 ---------------------------  ------------------------------- 
 f)    Date of                 4 May 2017 
        the transaction 
----  ----------------------  ------------------------------- 
 g)    Place of                London Stock Exchange, AIM 
        the transaction 
----  ----------------------  ------------------------------- 
 

-Ends-

Contact Details

 
 Clinigen Group plc                     Tel: [phone] 
                                         495 010 
 Shaun Chilton, Group Chief 
  Executive Officer 
  Martin Abell, Group Chief Financial 
  Officer 
 
 Numis Securities Limited               Tel: +44 (0) 20 
                                         7260 1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
  James Black / Tom Ballard 
  (Corporate Broking) 
 
 RBC Capital Markets - Joint            Tel: +44 (0) 20 
  Broker                                 7653 4000 
 Marcus Jackson / Elliot Thomas 
  / Jack Wood 
 
 Instinctif Partners (media             Tel: +44 (0) 20 
  relations)                             7457 2020 
 Melanie Toyne-Sewell / Alex 
  Shaw                                  Email: [e-mail] 
 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.

The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.

The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programmes for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).

Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital products.

For more information, please visit www.clinigengroup.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLLFSSESIAIID

(END) Dow Jones Newswires

May 09, 2017 10:47 ET (14:47 GMT)